Several other research firms have also recently commented on BTG. Deutsche Bank AG reaffirmed a buy rating on shares of BTG plc in a research report on Thursday, September 8th. Jefferies Group increased their price objective on BTG plc from GBX 840 ($10.40) to GBX 860 ($10.64) and gave the company a buy rating in a research report on Wednesday, June 29th. Stifel Nicolaus reaffirmed a buy rating on shares of BTG plc in a research report on Friday, June 24th. Finally, JPMorgan Chase & Co. reaffirmed a neutral rating and set a GBX 790 ($9.78) price objective on shares of BTG plc in a research report on Tuesday, August 23rd. Three analysts have rated the stock with a hold rating and four have given a buy rating to the company. The stock currently has a consensus rating of Buy and an average price target of GBX 799.57 ($9.90).
Shares of BTG plc (LON:BTG) opened at 699.00 on Thursday. The stock’s 50 day moving average price is GBX 631.14 and its 200 day moving average price is GBX 641.59. BTG plc has a 12 month low of GBX 504.00 and a 12 month high of GBX 739.50. The company’s market capitalization is GBX 2.68 billion.
In other BTG plc news, insider Soderstrom,Rolf sold 74,327 shares of the firm’s stock in a transaction dated Thursday, July 21st. The stock was sold at an average price of GBX 676 ($8.37), for a total value of £502,450.52 ($621,844.70).
About BTG plc
BTG plc is engaged in the business of healthcare, focusing on Interventional Medicine therapies for liver cancer, emphysema and vascular disorders, specialty pharmaceuticals for acute care uses, and a licensing business. The Company operates through three segments: Interventional Medicine, Specialty Pharmaceuticals and Licensing.
Receive News & Ratings for BTG plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BTG plc and related companies with MarketBeat.com's FREE daily email newsletter.